Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct 14;26(20):6215.
doi: 10.3390/molecules26206215.

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Navid Sobhani  1 , Giandomenico Roviello  2 , Alberto D'Angelo  3 , Raheleh Roudi  4 , Praveen Kumar Neeli  1 , Daniele Generali  5
Affiliations
Meta-Analysis

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Navid Sobhani et al. Molecules. .

Abstract

Importance: The protein p53 is an unequivocal tumor suppressor that is altered in half of all cancers. The immune system produces systemic p53 autoantibodies (p53 Abs) in many cancer patients. Objective: This systemic review and meta-analysis focuses on the prognostic value of p53 Abs expressed in the serum of patients with solid tumors. Data Sources: All the clinical investigations were searched on PubMed from the first study dated 1993 until May 2021 (date of submission of the manuscript). Study Selection: Studies were included that met the following criteria: (1) participants with cancer; (2) outcome results expressed in relation to the presence of a p53 antibody; (3) a primary outcome (disease-free survival, overall survival or progression-free survival) expressed as hazard ratio (HR). The following exclusion criteria were used: (1) insufficient data available to evaluate outcomes; (2) animal studies; (3) studies with less than 10 participants. As a result, 12 studies were included in the analysis. Data Extraction and Synthesis: PRISMA guidelines were used for abstracting and assessing data quality and validity by three independent observers. The summary estimates were generated using a fixed-effect model (Mantel-Haenszel method) or a random-effect model (DerSimonian-Laird method), depending on the absence or presence of heterogeneity (I2). Main Outcome(s) and Measure(s): The primary study outcome was to determine the prognostic value of p53 Abs from a large population of patients with solid tumors, as determined before data collection. Results: In total, 12 clinical studies involving 2094 patients were included in the meta-analysis, and it was determined that p53 Abs expression in the serum significantly correlated with poorer survival outcomes of cancer patients (95% CI 1.48 [1.24, 1.77]; p < 0.00001). Conclusions and Relevance: This is the first meta-analysis proving the diagnostic utility of p53-Abs for cancer patients in predicting poorer outcomes. The serum-p53 value (s-p53-value) may be useful for future theranostics.

Keywords: cancer survival prognostic biomarker; meta-analysis; p53; serum p53 antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of literature research strategy.
Figure 2
Figure 2
Meta-analysis of serum p53-antibodies. The prognostic value of p53 antibodies in the sera of cancer patients from eight clinical investigations was investigated in this meta-analysis.
Figure 3
Figure 3
The funnel plot of included studies.
Figure 4
Figure 4
Schematic representation of the significance of serological biomarker p53 antibodies (p53Abs) in prediction of cancer survival.
See this image and copyright information in PMC

References

    1. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 Mutations in Human Cancers. Science. 1991;253:49–53. doi: 10.1126/science.1905840. - DOI - PubMed
    1. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational Landscape and Significance across 12 Major Cancer Types. Nature. 2013;502:333–339. doi: 10.1038/nature12634. - DOI - PMC - PubMed
    1. Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild Type p53 Can Mediate Sequence-Specific Transactivation of an Internal Promoter within the mdm2 Gene. Oncogene. 1993;8:3411–3416. - PubMed
    1. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-Mdm-2 Autoregulatory Feedback Loop. Genes Dev. 1993;7:1126–1132. doi: 10.1101/gad.7.7a.1126. - DOI - PubMed
    1. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The Mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation. Cell. 1992;69:1237–1245. doi: 10.1016/0092-8674(92)90644-R. - DOI - PubMed